Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).

Pollock RF, Valentine WJ, Marso SP, Andersen A, Gundgaard J, Hallén N, Tutkunkardas D, Magnuson EA, Buse JB; DEVOTE study group.

Appl Health Econ Health Policy. 2019 Jul 2. doi: 10.1007/s40258-019-00494-3. [Epub ahead of print]

PMID:
31264138
2.

A Detailed Analysis of Perforations During Chronic Total Occlusion Angioplasty.

Hirai T, Nicholson WJ, Sapontis J, Salisbury AC, Marso SP, Lombardi W, Karmpaliotis D, Moses J, Pershad A, Wyman RM, Spaedy A, Cook S, Doshi P, Federici R, Nugent K, Gosch KL, Spertus JA, Grantham JA; OPEN-CTO Study Group.

JACC Cardiovasc Interv. 2019 Jun 19. pii: S1936-8798(19)31164-1. doi: 10.1016/j.jcin.2019.05.024. [Epub ahead of print]

PMID:
31255554
3.

Quality of Life Changes After Chronic Total Occlusion Angioplasty in Patients With Baseline Refractory Angina.

Hirai T, Grantham JA, Sapontis J, Cohen DJ, Marso SP, Lombardi W, Karmpaliotis D, Moses J, Nicholson WJ, Pershad A, Wyman RM, Spaedy A, Cook S, Doshi P, Federici R, Nugent K, Gosch KL, Spertus JA, Salisbury AC.

Circ Cardiovasc Interv. 2019 Mar;12(3):e007558. doi: 10.1161/CIRCINTERVENTIONS.118.007558.

PMID:
30871356
4.

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).

Pratley RE, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB; DEVOTE Study Group.

Diabetes Obes Metab. 2019 Jul;21(7):1625-1633. doi: 10.1111/dom.13699. Epub 2019 Apr 15.

PMID:
30850995
5.

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.

Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, Pratley RE, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP.

Circulation. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516.

PMID:
30566004
6.

Treating Leave Behind Lesions.

Marso SP.

Circ Cardiovasc Interv. 2018 Oct;11(10):e007367. doi: 10.1161/CIRCINTERVENTIONS.118.007367. No abstract available.

PMID:
30354648
7.

Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.

Nauck MA, Tornøe K, Rasmussen S, Treppendahl MB, Marso SP; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diab Vasc Dis Res. 2018 Sep;15(5):465-468. doi: 10.1177/1479164118783935. Epub 2018 Jun 27.

8.

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.

Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Diabetes Care. 2018 Aug;41(8):1783-1791. doi: 10.2337/dc17-2677. Epub 2018 Jun 14.

PMID:
29903847
9.

Relationship between left main coronary artery plaque burden and nonleft main coronary atherosclerosis: results from the PROSPECT study.

Shimizu T, Mintz GS, De Bruyne B, Farhat NZ, Inaba S, Cao Y, Marso SP, Weisz G, Serruys PW, Stone GW, Maehara A.

Coron Artery Dis. 2018 Aug;29(5):397-402. doi: 10.1097/MCA.0000000000000640.

PMID:
29781836
10.

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.

Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, Pratley RE, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Circulation. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898. No abstract available.

11.

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UK.

Pollock RF, Valentine WJ, Marso SP, Gundgaard J, Hallén N, Hansen LL, Tutkunkardas D, Buse JB; DEVOTE Study Group.

Diabetes Ther. 2018 Jun;9(3):1217-1232. doi: 10.1007/s13300-018-0430-4. Epub 2018 Apr 30.

12.

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).

Marso SP, Nauck MA, Monk Fries T, Rasmussen S, Treppendahl MB, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators.

Am J Cardiol. 2018 Jun 15;121(12):1467-1470. doi: 10.1016/j.amjcard.2018.02.030. Epub 2018 Mar 15.

13.

Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.

Marso SP, Hardy E, Han J, Wang H, Chilton RJ.

Diabetes Ther. 2018 Apr;9(2):551-564. doi: 10.1007/s13300-018-0370-z. Epub 2018 Feb 3.

14.

Safety of Degludec versus Glargine in Type 2 Diabetes.

Marso SP, Buse JB.

N Engl J Med. 2017 Nov 16;377(20):1995-1996. doi: 10.1056/NEJMc1712575. No abstract available.

PMID:
29141162
15.

Impact of subintimal plaque modification procedures on health status after unsuccessful chronic total occlusion angioplasty.

Hirai T, Grantham JA, Sapontis J, Cohen DJ, Marso SP, Lombardi W, Karmpaliotis D, Moses J, Nicholson WJ, Pershad A, Wyman RM, Spaedy A, Cook S, Doshi P, Federici R, Nugent K, Gosch KL, Spertus JA, Salisbury AC; OPEN CTO Study Group.

Catheter Cardiovasc Interv. 2018 May 1;91(6):1035-1042. doi: 10.1002/ccd.27380. Epub 2017 Oct 25.

PMID:
29068126
16.

Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.

Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP; Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups.

Diabetes Obes Metab. 2018 Mar;20(3):734-739. doi: 10.1111/dom.13125. Epub 2017 Nov 1.

17.

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).

Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, Barner Lekdorf J, Kvist K, Buse JB; DEVOTE Study Group.

Diabetologia. 2018 Jan;61(1):48-57. doi: 10.1007/s00125-017-4423-z. Epub 2017 Sep 15.

18.

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.

Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pratley RE, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J, Lehmann L, Kvist K, Buse JB; DEVOTE Study Group.

Diabetologia. 2018 Jan;61(1):58-65. doi: 10.1007/s00125-017-4422-0. Epub 2017 Sep 15.

19.

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group.

N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.

20.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

21.

Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures).

Sapontis J, Salisbury AC, Yeh RW, Cohen DJ, Hirai T, Lombardi W, McCabe JM, Karmpaliotis D, Moses J, Nicholson WJ, Pershad A, Wyman RM, Spaedy A, Cook S, Doshi P, Federici R, Thompson CR, Marso SP, Nugent K, Gosch K, Spertus JA, Grantham JA.

JACC Cardiovasc Interv. 2017 Aug 14;10(15):1523-1534. doi: 10.1016/j.jcin.2017.05.065.

22.

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group.

N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.

23.

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Mentz RJ, Bethel MA, Gustavson S, Thompson VP, Pagidipati NJ, Buse JB, Chan JC, Iqbal N, Maggioni AP, Marso SP, Ohman P, Poulter N, Ramachandran A, Zinman B, Hernandez AF, Holman RR.

Am Heart J. 2017 May;187:1-9. doi: 10.1016/j.ahj.2017.02.005. Epub 2017 Feb 12.

PMID:
28454792
24.

Liraglutide for weight management: a critical review of the evidence.

Mehta A, Marso SP, Neeland IJ.

Obes Sci Pract. 2017 Mar;3(1):3-14. doi: 10.1002/osp4.84. Epub 2016 Dec 19.

25.

Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials.

Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES, Armstrong EJ, Giri J, Bonaca MP, Pradhan A, Bavry AA, Kumbhani DJ.

JACC Cardiovasc Interv. 2017 Apr 10;10(7):712-724. doi: 10.1016/j.jcin.2017.01.027. Review.

26.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Marso SP, Holst AG, Vilsbøll T.

N Engl J Med. 2017 Mar 2;376(9):891-2. doi: 10.1056/NEJMc1615712. No abstract available.

PMID:
28249135
27.

Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States.

Amin AP, Patterson M, House JA, Giersiefen H, Spertus JA, Baklanov DV, Chhatriwalla AK, Safley DM, Cohen DJ, Rao SV, Marso SP.

JACC Cardiovasc Interv. 2017 Feb 27;10(4):342-351. doi: 10.1016/j.jcin.2016.11.049.

28.

The Outcomes, Patient Health Status, and Efficiency IN Chronic Total Occlusion Hybrid Procedures registry: rationale and design.

Sapontis J, Marso SP, Cohen DJ, Lombardi W, Karmpaliotis D, Moses J, Nicholson WJ, Pershad A, Wyman RM, Spaedy A, Cook S, Doshi P, Federici R, Thompson CR, Nugent K, Gosch K, Spertus JA, Grantham JA; OPEN CTO Study Group.

Coron Artery Dis. 2017 Mar;28(2):110-119. doi: 10.1097/MCA.0000000000000439.

PMID:
27755015
29.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators.

N Engl J Med. 2016 Nov 10;375(19):1834-1844. Epub 2016 Sep 15.

30.

Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Frandsen KB, Rabøl R, Buse JB.

Am Heart J. 2016 Sep;179:175-83. doi: 10.1016/j.ahj.2016.06.004. Epub 2016 Jun 18.

31.

Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus: Insights From the PROSPECT Study.

Kedhi E, Kennedy MW, Maehara A, Lansky AJ, McAndrew TC, Marso SP, De Bruyne B, Serruys PW, Stone GW.

JACC Cardiovasc Imaging. 2017 Apr;10(4):451-458. doi: 10.1016/j.jcmg.2015.12.023. Epub 2016 Jun 29.

32.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

33.

LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ.

Rutten GE, Tack CJ, Pieber TR, Comlekci A, Ørsted DD, Baeres FM, Marso SP, Buse JB; LEADER Investigators.

Diabetol Metab Syndr. 2016 Jun 2;8:37. doi: 10.1186/s13098-016-0153-5. eCollection 2016.

34.

Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (NCDR ACTION Registry-GWTG).

Pandey A, McGuire DK, de Lemos JA, Das SR, Berry JD, Brilakis ES, Banerjee S, Marso SP, Barsness GW, Simon DN, Roe M, Goyal A, Kosiborod M, Amsterdam EA, Kumbhani DJ.

Circ Cardiovasc Qual Outcomes. 2016 May;9(3):197-205. doi: 10.1161/CIRCOUTCOMES.115.002084. Epub 2016 May 10.

PMID:
27166210
35.

The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry CathPCI Registry.

Vora AN, Peterson ED, McCoy LA, Garratt KN, Kutcher MA, Marso SP, Roe MT, Messenger JC, Rao SV.

JACC Cardiovasc Interv. 2016 Apr 25;9(8):771-779. doi: 10.1016/j.jcin.2016.01.033. Erratum in: JACC Cardiovasc Interv. 2016 Jul 25;9(14):1522.

36.

Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.

Holman RR, Bethel MA, George J, Sourij H, Doran Z, Keenan J, Khurmi NS, Mentz RJ, Oulhaj A, Buse JB, Chan JC, Iqbal N, Kundu S, Maggioni AP, Marso SP, Öhman P, Pencina MJ, Poulter N, Porter LE, Ramachandran A, Zinman B, Hernandez AF.

Am Heart J. 2016 Apr;174:103-10. doi: 10.1016/j.ahj.2015.12.009. Epub 2015 Dec 21.

37.

Inpatient or Outpatient Status for Elective Percutaneous Coronary Intervention: Doctor, "You Gotta Let Me Know, Should I Stay or Should I Go?".

Kumbhani DJ, Marso SP.

Circ Cardiovasc Interv. 2016 Mar;9(3):e003699. doi: 10.1161/CIRCINTERVENTIONS.116.003699. No abstract available.

PMID:
26957419
38.

Association between health status and long-term mortality after percutaneous revascularization of peripheral artery disease.

Bunte MC, House JA, Spertus JA, Cohen DJ, Marso SP, Safley DM.

Catheter Cardiovasc Interv. 2016 May;87(6):1149-55. doi: 10.1002/ccd.26442. Epub 2016 Feb 19.

PMID:
26892836
39.

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial.

Masmiquel L, Leiter LA, Vidal J, Bain S, Petrie J, Franek E, Raz I, Comlekci A, Jacob S, van Gaal L, Baeres FM, Marso SP, Eriksson M; LEADER investigators.

Cardiovasc Diabetol. 2016 Feb 10;15:29. doi: 10.1186/s12933-016-0341-5.

40.

LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.

Petrie JR, Marso SP, Bain SC, Franek E, Jacob S, Masmiquel L, Leiter LA, Haluzik M, Satman I, Omar M, Shestakova M, Van Gaal L, Mann JF, Baeres FM, Zinman B, Poulter NR; LEADER investigators.

J Hypertens. 2016 Jun;34(6):1140-50. doi: 10.1097/HJH.0000000000000890.

41.

Influence of Total Coronary Occlusion on Clinical Outcomes (from the Bypass Angioplasty Revascularization Investigation 2 DiabetesTrial).

Damluji AA, Pomenti SF, Ramireddy A, Al-Damluji MS, Alfonso CE, Schob AH, Marso SP, Gilchrist IC, Moscucci M, Kandzari DE, Cohen MG.

Am J Cardiol. 2016 Apr 1;117(7):1031-8. doi: 10.1016/j.amjcard.2015.12.047. Epub 2016 Jan 14.

PMID:
26853953
42.

Predictors of Plaque Rupture Within Nonculprit Fibroatheromas in Patients With Acute Coronary Syndromes: The PROSPECT Study.

Zheng B, Mintz GS, McPherson JA, De Bruyne B, Farhat NZ, Marso SP, Serruys PW, Stone GW, Maehara A.

JACC Cardiovasc Imaging. 2015 Oct;8(10):1180-7. doi: 10.1016/j.jcmg.2015.06.014.

43.

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review.

Pandey A, Garg S, Matulevicius SA, Shah AM, Garg J, Drazner MH, Amin A, Berry JD, Marwick TH, Marso SP, de Lemos JA, Kumbhani DJ.

J Am Heart Assoc. 2015 Oct 12;4(10):e002137. doi: 10.1161/JAHA.115.002137. Review.

44.

Usefulness of Coronary Atheroma Burden to Predict Cardiovascular Events in Patients Presenting With Acute Coronary Syndromes (from the PROSPECT Study).

Shan P, Mintz GS, McPherson JA, De Bruyne B, Farhat NZ, Marso SP, Serruys PW, Stone GW, Maehara A.

Am J Cardiol. 2015 Dec 1;116(11):1672-7. doi: 10.1016/j.amjcard.2015.08.038. Epub 2015 Sep 10.

PMID:
26433274
45.

State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.

Kumbhani DJ, Marso SP, Alvarez CA, McGuire DK.

Curr Cardiovasc Risk Rep. 2015 Jan;9:4.

46.

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations.

Daniels GH, Hegedüs L, Marso SP, Nauck MA, Zinman B, Bergenstal RM, Mann JF, Derving Karsbøl J, Moses AC, Buse JB, Tuttle RM; LEADER Trial Investigators.

Diabetes Obes Metab. 2015 May;17(5):477-86. doi: 10.1111/dom.12444. Epub 2015 Feb 23.

47.

Transradial approach for coronary chronic total occlusion interventions: Insights from a contemporary multicenter registry.

Alaswad K, Menon RV, Christopoulos G, Lombardi WL, Karmpaliotis D, Grantham JA, Marso SP, Wyman MR, Pokala NR, Patel SM, Kotsia AP, Rangan BV, Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Garcia SA, Thompson CA, Banerjee S, Brilakis ES.

Catheter Cardiovasc Interv. 2015 Jun;85(7):1123-9. doi: 10.1002/ccd.25827. Epub 2015 Feb 3.

PMID:
25640902
48.

Procedural failure of chronic total occlusion percutaneous coronary intervention: Insights from a multicenter US registry.

Sapontis J, Christopoulos G, Grantham JA, Wyman RM, Alaswad K, Karmpaliotis D, Lombardi WL, McCabe JM, Marso SP, Kotsia AP, Rangan BV, Christakopoulos GE, Garcia S, Thompson CA, Banerjee S, Brilakis ES.

Catheter Cardiovasc Interv. 2015 Jun;85(7):1115-22. doi: 10.1002/ccd.25807. Epub 2015 Feb 3.

PMID:
25557905
49.

Percutaneous intervention of circumflex chronic total occlusions is associated with worse procedural outcomes: insights from a Multicentre US Registry.

Christopoulos G, Karmpaliotis D, Wyman MR, Alaswad K, McCabe J, Lombardi WL, Grantham JA, Marso SP, Kotsia AP, Rangan BV, Garcia SA, Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Thompson CA, Banerjee S, Brilakis ES.

Can J Cardiol. 2014 Dec;30(12):1588-94. doi: 10.1016/j.cjca.2014.07.007. Epub 2014 Jul 16.

PMID:
25442459
50.

LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

Steinberg WM, Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, Steen Ravn L, Moses AC, Stockner M, Baeres FM, Marso SP, Buse JB; LEADER Trial investigators.

Pancreas. 2014 Nov;43(8):1223-31. doi: 10.1097/MPA.0000000000000229.

Supplemental Content

Loading ...
Support Center